|
1
|
Bodily JM, Mehta KP and Laimins LA: Human
papillomavirus E7 enhances hypoxia-inducible factor 1-mediated
transcription by inhibiting binding of histone deacetylases. Cancer
Res. 71:1187–1195. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hildesheim A and Wang SS: Host and viral
genetics and risk of cervical cancer: A review. Virus Res.
89:229–240. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mansur CP and Androphy EJ: Cellular
transformation by papillomavirus oncoproteins. Biochim Biophys
Acta. 1155:323–345. 1993.PubMed/NCBI
|
|
5
|
Wang N, Zhan T, Ke T, Huang X, Ke D, Wang
Q and Li H: Increased expression of RRM2 by human papillomavirus E7
oncoprotein promotes angiogenesis in cervical cancer. Br J Cancer.
110:1034–44. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nordlund P and Reichard P: Ribonucleotide
reductases. Annu Rev Biochem. 75:681–706. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tanaka H, Arakawa H, Yamaguchi T,
Shiraishi K, Fukuda S, Matsui K, Takei Y and Nakamura Y: A
ribonucleotide reductase gene involved in a p53-dependent
cell-cycle checkpoint for DNA damage. Nature. 404:42–49. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Engström Y, Eriksson S, Jildevik I, Skog
S, Thelander L and Tribukait B: Cell cycle-dependent expression of
mammalian ribonucleotide reductase. Differential regulation of the
two subunits. J Biol Chem. 260:9114–9116. 1985.PubMed/NCBI
|
|
9
|
Zhou BS, Tsai P, Ker R, Tsai J, Ho R, Yu
J, Shih J and Yen Y: Overexpression oftransfected human
ribonucleotide reductase M2 subunitin human cancer cells enhances
their invasive potential. Clin Exp Metastasis. 16:43–49. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang K, Hu S, Wu J, Chen L, Lu J, Wang X,
Liu X, Zhou B and Yen Y: Overexpression of RRM2 decreases
thrombspondin-1 and increases VEGF production in human cancer cells
in vitro and in vivo: Implication of RRM2 in angiogenesis. Mol
Cancer. 8:11–22. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu X, Zhang H, Lai L, Wang X, Loera S,
Xue L, He H, Zhang K, Hu S, Huang Y, et al: Ribonucleotide
reductase small subunit M2 serves as a prognostic biomarker and
predicts poor survival of colorectal cancers. Clin Sci (Lond).
124:567–578. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Duxbury MS and Whang EE: RRM2 induces
NF-kappaB-dependent MMP-9 activation and enhances cellular
invasiveness. Biochem Biophys Res Commun. 354:190–196. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fan H, Villegas C, Huang A and Wright JA:
The mammalian ribonucleotide reductase R2 component cooperates with
a variety of oncogenes in mechanisms of cellular transformation.
Cancer Res. 58:1650–1653. 1998.PubMed/NCBI
|
|
14
|
Chabes AL, Björklund S and Thelander L: S
Phase-specific transcription of the mouse ribonucleotide reductase
R2 gene requires both a proximal repressive E2F-binding site and an
upstream promoter activating region. J Biol Chem. 279:10796–10807.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang M, Wang J, Yao R and Wang L: Small
interfering RNA (siRNA)-mediated silencing of the M2 subunit of
ribonucleotide reductase: A novel therapeutic strategy in ovarian
cancer. Int J Gynecol Cancer. 23:659–666. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fulda S and Vucic D: Targeting IAP
proteins for therapeutic intervention in cancer. Nat Rev Drug
Discov. 11:109–124. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Vermeulen K, Van Bockstaele DR and
Berneman ZN: The cell cycle: A review of regulation, deregulation
and therapeutic targets in cancer. Cell Prolif. 36:131–149. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen HZ, Tsai SY and Leone G: Emerging
roles of E2Fs in cancer: An exit from cell cycle control. Nat Rev
Cancer. 9:785–797. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Su YF, Wu TF, Ko JL, Tsai HT, Tee YT,
Chien MH, Chou CH, Lin WL, Low HY, Chou MY, et al: The expression
of ribonucleotide reductase M2 in the carcinogenesis of uterine
cervix and its relationship with clinicopathological
characteristics and prognosis of cancer patients. PLoS One. 9:e
916442014. View Article : Google Scholar
|
|
21
|
Pecorelli S: Revised FIGO staging for
carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol
Obstet. 105:103–104. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang N, Zhou Y, Zheng L and Li H: miR-31
is an independent prognostic factor and functions as an oncomir in
cervical cancer via targeting ARID1A. Gynecol Oncol. 134:129–137.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Molina JR and Adjei AA: The Ras/Raf/MAPK
pathway. J Thorac Oncol. 1:7–9. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li XD, Zhang YJ and Han JC: Betulin
inhibits lung carcinoma proliferation through activation of AMPK
signaling. Tumour Bio. l35:1–11158. 2014.
|
|
26
|
Liu X, Zhou B, Xue L, Yen F, Chu P, Un F
and Yen Y: Ribonucleotide reductase subunits M2 and p53R2 are
potential biomarkers for metastasis of colon cancer. Clin
Colorectal Cancer. 6:374–381. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Souglakos J, Boukovinas I, Taron M, Mendez
P, Mavroudis D, Tripaki M, Hatzidaki D, Koutsopoulos A,
Stathopoulos E, Georgoulias V and Rosell R: Ribonucleotide
reductase subunits M1 and M2 mRNA expression levels and clinical
outcome of lung adenocarcinoma patients treated with
docetaxel/gemcitabine. Br J Cancer. 98:1710–1715. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kang W, Tong JH, Chan AW, Zhao J, Wang S,
Dong Y, Sin FM, Yeung S, Cheng AS, Yu J and To K: Targeting
ribonucleotide reductase M2 subunit by small interfering RNA exerts
anti-oncogenic effects in gastric adenocarcinoma. Oncol Rep.
31:2579–2586. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ferrandina G, Mey V, Nannizzi S, Ricciardi
S, Petrillo M, Ferlini C, Danesi R, Scambia G and Del Tacca M:
Expression of nucleoside transporters, deoxycitidine kinase,
ribonucleotide reductase regulatory subunits, and gemcitabine
catabolic enzymes in primary ovarian cancer. Cancer Chemother
Pharmacol. 65:679–686. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kretschxmer C, Sterner-Kock A, Siedentopf
F, Schoenegg W, Schlag PM and Kemmner W: Identification of early
molecular markers for breast cancer. Mol Cancer. 10:152011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Morikawa T, Maeda D, Kume H, Homma Y and
Fukayama M: Ribonucleotide reductase M2 subunit is a novel
diagnostic marker and a potential therapeutic target in bladder
cancer. Histopathology. 57:885–892. 2010. View Article : Google Scholar : PubMed/NCBI
|
